0000895345-11-000166.txt : 20110513 0000895345-11-000166.hdr.sgml : 20110513 20110513105426 ACCESSION NUMBER: 0000895345-11-000166 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20110513 DATE AS OF CHANGE: 20110513 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INSPIRE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001040416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043209022 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60379 FILM NUMBER: 11838576 BUSINESS ADDRESS: STREET 1: 4222 EMPEROR BLVD STE 200 CITY: DURHAM STATE: NC ZIP: 27703-8466 BUSINESS PHONE: 9199419777 MAIL ADDRESS: STREET 1: 4222 EMPEROR BLVD STREET 2: STE 200 CITY: DURHAM STATE: NC ZIP: 27703-8466 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Monarch Transaction Corp. CENTRAL INDEX KEY: 0001517906 IRS NUMBER: 451540007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: ONE MERCK DRIVE STREET 2: P.O. BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889 BUSINESS PHONE: (908) 423-1000 MAIL ADDRESS: STREET 1: ONE MERCK DRIVE STREET 2: P.O. BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889 SC TO-T/A 1 dstota4-inspire_monarch.htm dstota4-inspire_monarch.htm
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE TO

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
(Amendment No. 4)

INSPIRE PHARMACEUTICALS, INC.
(Name of Subject Company (Issuer))

MONARCH TRANSACTION CORP.
MERCK & CO., INC.
(Name of Filing Persons (Offerors))

COMMON STOCK, PAR VALUE $.001 PER SHARE
(INCLUDING ASSOCIATED PREFERRED STOCK PURCHASE RIGHTS)
(Title of Class of Securities)

457733103
(CUSIP Number of Class of Securities)
 
Richard N. Kender
Senior Vice President, Business Development and Corporate Licensing
Merck & Co., Inc.
One Merck Drive, PO Box 100
Whitehouse Station, NJ 08889-0100
(908) 423-1000
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications on Behalf of Filing Persons)

Copies to:
David N. Shine, Esq.
Fried, Frank, Harris, Shriver & Jacobson LLP
One New York Plaza
New York, New York 10004
(212) 859-8000

 
CALCULATION OF FILING FEE
 
Transaction Valuation*
  
Amount of Filing Fee**
$481,393,285
  
$55,889.76

*
Estimated for purposes of calculating the filing fee only. This amount is based on the offer to purchase at a purchase price of $5.00 cash per share (i) all 83,292,192 outstanding shares of common stock of Inspire; (ii) all restricted stock units with respect to 1,665,719 shares of common stock of Inspire; and (iii) all outstanding options respect to 11,320,746 shares of common stock of Inspire, in each case as of April 1, 2011, the most recent practicable date.
**
The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #5 for fiscal year 2011, issued December 22, 2010, by multiplying the transaction valuation by 0.00011610.
 
x
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 
  Amount Previously Paid: $55,889.76 Filing Party: Monarch Transaction Corp.
  Form or Registration No.: Schedule TO-T  Date Filed:   April 15, 2011
                                                                                                                                                                                                                                               
¨           Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes to designate any transactions to which this statement relates:

x
third-party tender offer subject to Rule 14d-1
o
going-private transaction subject to Rule  13e-3
o
issuer tender offer subject to Rule 13e-4
 
o            amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer. x

 
 
 
 
 
This Amendment No. 4 to the Tender Offer Statement on Schedule TO (this “Amendment”) filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 13, 2011, amends and supplements the Tender Offer Statement on Schedule TO filed on April 15, 2011 (as further amended and supplemented, the “Schedule TO”), relating to the offer by Offeror (as defined below) to purchase all of the outstanding shares of common stock, par value $0.001 per share (together with the associated preferred stock purchase rights, each a “Share” and collectively, the “Shares”), of Inspire Pharmaceuticals, Inc., a Delaware corporation (“Inspire”), at a purchase price of $5.00 per Share, net to the seller in cash, without interest thereon and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated April 15, 2011 (which, together with this Amendment and any previous or future amendments and supplements thereto, collectively constitute the “Offer to Purchase”), and in the related letter of transmittal (the “Letter of Transmittal”), copies of which are attached to the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, collectively constitute the “Offer”). The Schedule TO (including the Offer to Purchase) filed with the SEC by Monarch Transaction Corp., a Delaware corporation (“Offeror”) and Merck & Co., Inc., a corporation formed under the laws of New Jersey (“Merck”), on April 15, 2011, as amended by this Amendment and the Solicitation/Recommendation Statement on Schedule 14D-9 filed with the SEC by Inspire on April 15, 2011 (as amended or supplemented from time to time, the “Schedule 14D-9”), contain important information about the Offer, all of which should be read carefully by Inspire stockholders before any decision is made with respect to the Offer. The Offer is made pursuant to the Agreement and Plan of Merger, dated as of April 5, 2011, by and among Merck, Offeror and Inspire.

Documentation relating to the Offer has been mailed to Inspire stockholders and may be obtained at no charge at the website maintained by the SEC at www.sec.gov and may also be obtained at no charge by directing a request by mail to Georgeson Inc., the Information Agent for the Offer, at 199 Water Street, 26th Floor, New York, NY 10038, or by calling toll−free at (800) 279-6913.

All information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated by reference herein in response to Items 1 through 9 and Item 11 of the Schedule TO, and is supplemented by the information specifically provided in this Amendment. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Offer to Purchase or in the Schedule TO.

Items 1 through 9 and Item 11.
The information set forth in the Offer to Purchase in the section entitled “Other Information” is hereby amended and supplemented by adding the following paragraph after the second paragraph on page 2:

“On Friday, May 13, 2011, Offeror successfully completed the Offer, which expired at 12:00 midnight, New York City time, at the end of the day on Thursday, May 12, 2011 (the “Expiration Date”).  The Depositary has indicated that, as of the Expiration Date, approximately 72,544,987 Shares (excluding Shares subject to guarantees of delivery) had been validly tendered and not properly withdrawn from the Offer, representing approximately 75.4% of the outstanding Shares on a fully diluted basis (as determined pursuant to the Merger Agreement). All Shares that were validly tendered and not properly withdrawn in the Offer have been accepted for purchase and payment at the Offer Price, and all holders of these Shares will be paid promptly in accordance with the terms of the Offer.

Pursuant to the terms and conditions set forth in the Merger Agreement, Merck intends to complete the acquisition of Inspire promptly through the merger of Offeror with and into Inspire, with Inspire as the Surviving Corporation.  Pursuant to the terms and conditions of the Merger Agreement, Offeror will exercise its top-up option  to purchase a number of newly issued Top-Up Option Shares directly from Inspire at the Offer Price, when taken together with Shares purchased in the Offer, constituting at least 5,000 Shares more than 90% of the Shares outstanding (after giving effect to the issuance of the Top-Up Option Shares).  As a result of the Offer and following the purchase of the Top-Up Option Shares, Offeror will own at least 90% of the outstanding Shares, which is sufficient to enable Offeror to effect the Merger without a vote or meeting of Inspire’s stockholders through the “short-form” merger provisions of the DGCL.
 
Merck expects to complete the acquisition of Inspire on May 16, 2011 through the Merger described above.  Pursuant to the terms of the Merger Agreement, at the Merger Effective Time each Share (other than Shares held in the treasury of Inspire, Shares held by Merck, Offeror or any direct or indirect subsidiary of Merck or Inspire and any Shares held by any person who is entitled to and properly demands appraisal of such Shares under the DGCL) will be cancelled and converted into the right to receive the Merger Consideration.  After the Merger, Inspire will be a wholly-owned subsidiary of Merck, shares of Common Stock will cease to be traded on the NASDAQ and Inspire will no longer have reporting obligations under the Exchange Act.  The press release announcing the completion of the Offer is attached hereto as Exhibit (a)(5)(C) and is incorporated by reference herein.”
 
Items 12.
 
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:
 
 
Exhibit (a)(5)(C)
Press release issued by Merck, dated May 13, 2011.
 
 
 
 
 
SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

             
       Dated: May 13, 2011
  
MONARCH TRANSACTION CORP.
   
 
By:
  
 
/s/ Katie Fedosz
       
Name:
  
Katie Fedosz
       
Title:
  
Assistant Secretary
 
       Dated: May 13, 2011
  
 
MERCK & CO., INC.
   
 
By:
  
 
/s/ Katie Fedosz
       
Name:
  
Katie Fedosz
       
Title:
  
Senior Assistant Secretary

EX-99.1 2 dstotaex99_1.htm dstotaex99_1.htm
 
 
 
Exhibit (a)(5)(C)
 
 
 
FOR IMMEDIATE RELEASE
 
Media Contact:
Ian McConnell
(908) 423-3046
  
Investor Contact:
Carol Ferguson
(908) 423-4465
 
 
Merck Announces Successful Completion of Tender Offer for Shares of Inspire Pharmaceuticals, Inc. With Over 75 Percent of Shares Tendered
 
WHITEHOUSE STATION, N.J., May 13, 2011 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Monarch Transaction Corp., its wholly-owned subsidiary (“Monarch”), successfully completed the cash tender offer for all of the outstanding shares of common stock (together with the associated preferred stock purchase rights, the “Shares”) of Inspire Pharmaceuticals, Inc. (“Inspire”), which expired at 12:00 midnight, New York City time, on Thursday, May 12, 2011.  Computershare, Inc., the Depositary for the tender offer, has indicated that, as of the expiration of the tender offer, approximately 72,544,987 Shares (excluding Shares subject to guarantees of delivery) had been validly tendered and not properly withdrawn from the tender offer, representing approximately 75.4 percent of the outstanding Shares on a fully diluted basis (as determined pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) among Monarch, Merck and Inspire, dated as of April 5, 2011).  All Shares that were validly tendered and not properly withdrawn in the tender offer have been accepted for purchase and payment at the offer price of $5.00 per share in cash, without interest and less any applicable withholding taxes, and all holders of these Shares will be paid promptly in accordance with the terms of the offer.
Merck intends to complete the acquisition of Inspire promptly through the merger of Monarch with and into Inspire, with Inspire as the surviving corporation.  Pursuant to the terms and conditions of the Merger Agreement, Monarch will exercise its top-up option to purchase a number of newly issued Shares (the “Top-Up Option Shares”) directly from Inspire at the same price per share paid in the tender offer in an amount which, when taken together with the Shares purchased in the tender offer, constitutes at least 5,000 Shares more than 90 percent of the Shares outstanding (after giving effect to the issuance of the Top-Up Option Shares).  As a result of the tender offer and following the purchase of the Top-Up Option Shares, Monarch will own at least 90 percent of the outstanding Shares, which is sufficient to enable Monarch to effect the merger without a vote or meeting of Inspire’s stockholders through the “short-form” merger provisions of Delaware law.
Merck expects to complete the acquisition of Inspire on May 16, 2011 through the merger described above.  Pursuant to the terms of the Merger Agreement, at the effective time of merger the remaining Inspire stockholders (other than Inspire, Merck and Monarch and any of their respective direct or indirect subsidiaries, or those stockholders who are entitled to and properly exercise appraisal rights under Delaware law) will become entitled to receive $5.00 per Share in cash, without interest and less any applicable withholding taxes, the same price that was paid in the tender offer.  After the merger, Inspire will be a wholly-owned subsidiary of Merck, Inspire shares will cease to be traded on the NASDAQ Global Market and Inspire will no longer have reporting obligations under the Securities and Exchange Act of 1934, as amended.
 
About Merck
Today's Merck is a global healthcare leader working to help the world be well.  Merck is known as MSD outside the United States and Canada.  Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.  We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.  For more information, visit www.merck.com.
 
Forward-looking statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care  legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the United States and internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2010 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
# # #
 GRAPHIC 3 mercknewsrelease.jpg begin 644 mercknewsrelease.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`! M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@`````` M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$! M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H* M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%(# M"P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/W\HHHH`JZSJ^F:!IEQK>M7\5K9VD#375S/($2*-1EF8G@``$Y- M?EK^VO\`\%XO%EQX@O/`/['-C;6>G6TC1/XRU*V$LMT1P6@A<;43/1G#$]=H M[^E?\%^/VG]9^'OPET#]G7PEJ36\_C)Y;G7'BD*O]A@90L7'\,DC<^HC([FO MR)-?9%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%'?%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110!7U#4K+2K&;4]4O(K:WMXVDGGGD")&@&2 MS,>``.237P7^U)_P7K^"?PLUJY\(?`'P;)XYO;9C'+J\ER;;3@X/1&P7F'N` M`>Q-><_\%XOVV_$&G:I;?LX[Y0>H MK\P:^QR7A^EB*"Q&)U3V7EW9_/\`XB>*F.RS,9Y7E#2E#2=1I-WZQBGIILVT M]=%M<_3SX-_"GP]_P72N-5^-GQO\1W7A#5/!KQ:/:Z1X7"R0FW<-,)6,X9MQ M8L.,#"BNY_XAW?V>NWQT\8?]^+;_`.(KY"_X([_MDZ)^RG^T?)H7Q`U,6OA7 MQK!'8:E=.?DL[E6)MYV]%!9D8]@^>U?N+;S0W,"7%O*LD_P#HNOC#_OQ;?_$4?\0[O[/?_1=?&'_?BV_^(K]"Z1CQUKR_ M[-.L`/\`$\,@#$=R58GT!K-_X+U_MGZ#J=A8?L>>`M62XGBN MX]0\820L&6$J,P6Q(_BR?,8=L)ZFOS!SZ5]3EV7?VI@E5Q]Y2>SV:73_`#/Q M/BKBU\%\1RP7#+5.C!+GBES1E4ZWO=Z*T79K5']+WPN^*WP^^-/@FQ^(OPO\ M5V>LZ-J,>^UO;.3JD=58="I`(/45T5?AM_P`$BOVV=?\`V8/VB=.^'^O: MRY\%^,KZ.QU6TD?,=K+U3 M/W'@?B^AQCE'UE1Y:D7RSCV?=>3Z?-=`K\CO^"@G_!?O]J#]DS]L+QO^SUX' M^%7@R_TKPUJ$4%G=ZDER9Y%:".0E]D@&*;Q MM/75-)\]98+MT/V?/F.R[6D"H?\`?![5^N(SWK^0^W;Q3X"U[3M<@6YTW4+? M[/J.F3X*.N=LL,R'_OE@:_I^_96_;-\$_&S]A+0?VQ-K^-/$4MQ;6:`NZJ[;885'HL81![+5']F]2O[1O@%6'(\;Z4#_X&15J MH12M8R=23EN?N%_P65_X*Y?'7_@G1\5_!_@/X3^`?#6KVWB'P_+?W4NN+,7C MD68Q@+Y;J,8'>OC?_B*&_;,_Z(G\/O\`OW=__':VO^#IO_DX_P"&'_8E7/\` MZ5M6C_P;Y_L$?LC_`+7?P,\?>*?VB_@KIWBC4-)\60VFG7-[-,IAA-JCE!Y; MJ,;B3S4I1C!-HMN;J63.43_@Z%_;+9@I^"?P_P"2!Q'=_P#QVOL#_@JW_P`% M??CQ^PAIGPFO?AI\/_#.J-X]\+2ZGJ8UA9B()%6W(6/8X^7]ZW7/05[=_P`. M4/\`@E]U_P"&1]!_\"KK_P".U^?W_!TII.G>'_&GP1T'1[58+2R\-ZI!:PJ3 MB.-)+5549]``*E.$I))#?M(P;;.1_P"(H;]LO_HBGP^_[]W?_P`=KH?AU_P= M+?'^P\0PM\5/V;O"NHZ47'VE=$O[BVN%7N4,A=2?8C\JO_\`!M]^RI^S?^T; M\/\`XI7_`,=_@KX>\63:7K.FQZ=+K>G+.;='BF+*F[H"5!/TJM_P<&?\$R?V M;?V8_A_X;_:6_9W\*6WA4:CKXTC6_#UBY%M.SQ221SQ(2?+8>6P8+\I#`X!' M-/DYN6Q-ZG)S7/U9_8Y_;*^"7[.8,OU.ZOH#_@F%_P;R>`/%OPSTGX[_MQKJ%S./^"%7_!,+QIXI MW,%S&><-N,A!//\`$"#WIMTHNUB5&M+6YY]\#/\`@LSXJ_:'_P""H^//^"=,O_!.'_@E MU^U%\.M+\=?V_H/B"T&H^'[N>+9=10A(D:*<`;2RL/O+PPP<`\5^6'_!*T'_ M`(>-?!P'MXYM,?K51C"2=A2E--7/Z>O$&OZ+X5T*\\3>(]3@LM/T^UDN;V\N M9`D<,2*6=V)X``!)/M7XQ_'?_@Y[^-.G_%[7]-^`'P@\*7?@^UU!X="OM;6X M-S=PI\OG.$=0N\@L%QPI`/-=;_P<5_\`!3,V<$G[`WP4\0?O9D27XC:A:3G`@]6X>0>FU>["OG7_@A%_P3,?\`:_\`C0/C_P#%K0#)\.O!%\CB"XC_ M`'>M:DN&2W&>&CCX>3L?E7^(U,(I1YI%SG*4N6)^RG_!/;XL?M/_`!V_9OTK MXQ_M4^"]%\-ZSXB'VO2]"TB&5&MK%@/*:;S68B1Q\^WC"LH/.:]QIL<:11B. M-%55&%51@`>@IU9-W9LE9!1112&%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110!_/I_P4RUC4]<_;S^)]YJ_F>:GB9X461L[8XXT1`.>! MM4$#WKPJOM?_`(+E_LWZO\*/VLY?C'9Z*_6*<92KKWO:2?JI.Z?S33%'2 MOO'_`()E?\%'?VW?"EQ:?`_PG\)M3^+.@V@5(+&,.+K2XL\`7."JQ^BR\#&` M1TKYF_8K_92\6_MD_'S2O@WX:F:UMI=USK>IA,BQLDQYDGH6.0J@]68>]?O= M^S_^SK\)?V9OAW9_#/X0>$[?3-/M8P))%0&:ZDQS+-)C,CD\DGZ#`XKR.(

GS,M?!'_!27_@I+ M^W3\(]&N/"?A7]F75?AWIMW^Y'C3472]8Y[0R0[H(G/JQ9O0=Z_2.L[Q3X2\ M,^.-`NO"OC#0;/4]-O8C%>6-_;K+%,AZAE8$&OBL'B25V.69F/))/.34%?77_!67_@GK;?L9?$ZT\8?#:WF/@/Q3(YTQ)'+G M3;E1N>U9CU7!W(3SM!!SMR?D6OU/"8FCB\/&K2^%_P!6/XISS*,?D6:5<%C% M:I!Z^=]4T^J:U)+2XGM;J*ZM9626.0-&Z'!5@<@@]CFOZ8_AW?W>J^`M$U34 M(V6XN=(MI9U;J':)2?U-?SU?L8?L\:]^U%^TGX7^$.BV32P7FHI-J\H!VP6, M9#SNQ[?("H]68#O7]%-E:PV5M'9VR;8XHU1%'8`8`_*OD.+:L'4I4UNKO[[? MY'[SX$X/$T\/C,5)6A)PBO-QNW]UU]Y+7\T'_!:S_E)_\6O^PU;_`/I'!7]+ M]?S0?\%K/^4G_P`6O^PU;_\`I'!7RE'=G[U7V1Z3^WM^R*S_`/!,C]FS]M+P MOIGW/!\7A[Q8\:]O-E>TF;\?,C)/J@KR3X3?\%#O&_PO_P""=GQ#_88LFN#% MXP\06ES87B/Q:V;9-]#UX\PQ0#`ZAY,]:_9#]C[]G/P_^UG_`,$+_!O[/WB- M$\OQ'\-C!:S.N?L]TLCO!,/=)51OPK^>[QCX1\0^`?%VJ>!/%>FR6FJ:-J$U MCJ%K(N&CGB(M,\W0_AEX M0O9[9I$RDFJ3VTJ0#D8)1/,D]B$-?)'[.7_)R'@+_L>=*_\`2V*OW[_X)D_L MBC]D+_@EDWAS6M,^S^)/$_AB^U_Q-O3#B>XMF,<3=_W<(C3'J&]:_`3]G'_D MY#P%_P!CSI7_`*6Q4XRYFPE&UC]$_P#@Z;_Y./\`AA_V)5S_`.E;5\,_LT_\ M%`OVM_V//#VI>$_V=?C)<^&;#5[U;O4+>"TMY!-,$"!R948CY0!Q7W-_P=-_ M\G'_``P_[$JY_P#2MJ]:_P"#8;X?^`O&/[.?Q*NO%W@G2-5EA\;0)%)J6F13 MLB_8T.`74D#/847Y::933E5LCX2T3_@MW_P4XNM:LK6Y_:KOVCEO(DD7^S++ ME2X!'^I]*^J_^#J%VD^(/P6=SDGP_JQ)]?WMK7Z]K\$/@NK!E^$/A<$'((T" MVX/_`'Q7Y$?\'58`^)7P:`'']AZQC_O];5G&2E-614H.,'=W/(_^"2O[97QS M_82_9`^+7Q\^%7P-T[QOI%EXKTF'Q1%=:I+;R:=$\,PBN`$C??'O.UB<;=RG MIG'AW_!07_@J#^T9_P`%)?$.CV?Q$TVQTG1-'E8Z)X5T%)&C$\@"F1RQ+32D M?*.@`)`')S]Y?\&QW@OPM\1_@+\=/`/C?18-2T?6=0T^SU*PN4W1SPR6UPKH MP]"":^`O^"D'[$_CS_@G+^UG>>`K*ZO8](:Y&K>`_$",5>6UW[HR'&,30N-C M8YRH;^(5:Y7-]S-\RIKL?5_[%O[!?QG_`&1?^";7[0'[:GQ:\+WN@>(/$/PV MN-)\)Z3=1M%>6]A,RB>>1",Q^9E-JGG:A)`R*^'/V#?`WA_XE?MH_"SP'XJB M633=3\Q.`5DC\]6*'/&&QM_&OVR_8+_`&NO#O\`P5^_X)U^+_@5X]U* M"'Q_%X6GT+Q7;Y`,SR0LEOJ"+G[KL`Q[!U8=,9_"-8_B5^R_\=8UU&PETOQ9 MX#\3H\EO,"&@O+2<-@^HW(/J#[T1;;=PDDDFMC^M1$2-!'&H55&%`&`!2UXQ M^PQ^VY\(/VZ_@9I?Q<^&6NVYNWMD77]",RFYTJ[`^>&1,Y`SDJW1EP17LY(' M)-<[33LSK335SYO_`."O?_*-'XQ_]B?+_P"C$K^>O]@*W^(-W^V9\.[7X3WM ME;>)Y/$"KX>N-20M;QWAC?R6D`Y*A]N:_?'_`(*C?%WX:?$?_@G?^T!X:\!^ M-=/U>\\,^'&L]>BL+@2_8KA_+D$3E>`^T@E<5^%G_!*W_E(U\&QZ>.K3 M^M;T[\AS56G-'DWQ>L?B1I7Q<\1:?\;8]0_X2J'7;A?$XU!C]I-YYA\XN6ZL M6R<].0>E?TR?\$R-6_9QUG]B#P!<_LK0)#X1314CAMV*FXBNEXN%N-O6?S=^ M\]R'O]*LT2W^(EG:11\$/BCKQC^'GCR\CBFEN)?W>D:B?EBN1GA4?B M.3VVM_#2E^\A=!%^RJ69_09121R)*@DC8,K#*LIR"*6L#J"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`***@EU72X+M=/FU*W2=\;(&F4.V>F!G)H`GHHJ"\U/3 M=/9%O]0@@,AQ&)I0NX^V3S0!/1110`4444`%%%%`!1110`4444`%%47\3>&X MG,E>IEV;XO+;JGK%]'M_P#XGBS@+(^+TIXE.% M6*LIQLG;L[Z->NW1H_,G_@AWH7@;]FS1/'GB;]H36;#P3XDU.]M;2SL/%]RF MG7+6D:LY=([@HQ1G?&X#!*8[5]]#]JC]F/''[1'@?_PJK3_XY7YU?\'$GP@U M:+Q5X!^.EK9L]C-8SZ-?2K'Q%*K^=$&/;<&DQ_N&OS1*KG@"OH8913SV/UV5 M1IRZ;VMI;\#\HQ''F+\-*KX>I855(T=IN3BY*7O,?_P!`4?\`P-_Y'[<_\%4_%GP#_:+_`&+?$_@CP1\4O#'B'Q);26M[ MX=TK1];M[F[N+E)D&R**-R[L8VD&U02%=2MK1FL?"HFUC4I MO+RJ+'&R1@GL3(Z8^AK]V0H]*YJ^,J<.)X2B^9OWKOI?2UOE<]G+,@PGBW)9 MYF,714?W:C!_&HZWF3VQ]$`8[T8`HKY6O7JXFJZE1W;/VW+?0U_1]36@A8[FA4D]25%3"?(SKJ0YT?.G_!(S2=5T/\` MX)M?"#2=;TRXLKN#PE&L]K=P-')&WF2<,K`%3[$5\7?M>_\`!(V7XI_\%JO! M?CW3_#);P#XSC/B;Q>Z0_N8[BP\L3PMV_?N;?@]3+(><&OU=554;54`#H`*" MJEMQ49`X.*%-IM@X)I)G-_%ZV=OA#XGM+.`LQ\.WB111KDD^0X``'\J_E\_9 MY^"GQEM/VB/`MW=?"/Q1%%'XVTMY)9/#]RJHHO(B6)*<`#G-?U4$`C!%,%O; M@Y$"?]\BB$^1$SI\[3N?B_\`\'.WP]\?^,OVA_AI=^$/`NL:K%#X-N4FETW3 M)9U1OM1(!**0#CG%?`_P?\<_\%!OV?=*N]"^!FK_`!6\(V5_<"XO;7P]!?VL M<\H4*'=8U`9MH`R>PK^IEH8G.7B4X]5I/L]O_P`\$_[Y%6JJ2LT3*BW*]S^9 M=?VNO^"NVX`_'+X[D9&,_!OPY^+D/C#PCJFDO/KFEM`NIZ?);F0"&?)7>HSC(Z>M M?6'_``5H_P""?>B_M_?LOWWA'3+6&/QKX>#ZAX*U&0`%;D+\ULS=HYE&P]@= MK?PU]0I'''GRXU7/7`Q3JAR;ES&D86ARL_F*_8G^(7[7G[`7[3VE_&7PI\&/ M%XETJ[:R\2:*V@W(34+,OMGMGPF,\94\[7537Z>?\%,/^"3'A+_@IEX#TO\` M;>_8_:+2O&NLZ-% MORBG*JH-J*`!V`JG4N[HA4K)IO0_E4O=%_;-_8%^)LK3VOC?X8^);9C$]S"9 M[(R@'D"1<),GT+*:ZKQK_P`%4O\`@HI\5]`/@KQ'^UMXPNK.:/RWMK"\6W>9 M>A5F@57?/N3FOZ_9T_ M9]\(ZG_;7A7X%^#]-O`^X7=AX:M89`?4,L8(Z57M5U1/L6GHS\@_V"?@S\9_ M"O\`P1'_`&EXO&7PQ\1V%WXD;[3HL6HZ5,D^HIY40,D:,N^0;L\@<^]?)7_! M+_X/_%O1?^"A7PAU;6/A9XDM+6#QM:O/OO"OB;2H+[3M2M)+:^LK MF,-'/"ZE71@>H()!K^;G_@IM_P`$QOBK^QC^T]JG@KP#X$US6O!NKEM0\(:E MI^G2W(6U9N;>1D4XDB;Y#GDC:W>OZ4Z:\4,O`EHD=GJ>M:;-%_:^F`[8WWR*-TL7$;-O^#8?_@L+IG[7?PAT.\D_9F^-]Z]MXFT&Q0F'30\GF7%FJC@2VS$W-KT+ M1&2$'`D-=?\`\':_CGPC\3O%?[$OQ'\`>(;75]"U[Q%?ZAH^J64H>&[M9I=' MDBE1AU5E8$'T-"W`_=]W2-#)(P55&22>`*\`\4?\%7/^"97@KQT_PS\6?M^? M"'3]=BF\F?3KGX@6"O#+DCRY#YN(WR,;6(/3CD5^?W_!W#^W?\4O@9\#OAK^ MQ3\'/B&OA2[^-6L7,?BKQ`+[[,;;1[=H(VA>;713$EQ%,EV#: M_-DJD6U5``(8Y)`/UTO/B)X`T_P'-\4[_P`<:1#X9M],;49_$4NI1+8QV:H9 M&N6G+>6(@@+%\[0HSG%5/A9\8OA)\<_"B^._@K\3_#WB[1&N'@76/#.LP7UJ M94QO3S869=RY&1G(SS7X<_\`!O7\;/#'@O\`;F_:%_X(A6?QSM?BQ\!=1T75 M[OX;:O%J\>H6K69:..:WAEB+1E)K6[)D5#L$UO(0%,CY]%_X-/\`Q=KG[,WQ M'_:D_P""6'Q+U1EU'X6_$.75=-2X;!DB$C:?=RKG_EG_`*+9R`C@^?G^+D`_ M7`?M)_L[M\8/^&>E^._@X^/MN[_A"?\`A);7^UL>3Y^?LGF>=CROWGW?N?-T MYK1^*OQD^$7P*\*GQU\;/BCX>\(:(+A+*HX9.8+(RFSBN".X M2'^U)/\`ME0!^N7C+X\_`_X=?#)/C5\0/C%X7T/P=+:Q7,7BK5]?M[;3GAD7 M?'(+F1Q&5=2&4AL,#D9KS?X0?\%.O^"=7Q_\70_#_P""_P"W!\+/$NNW,HCM M-%TKQO927=RYZ+%%YF^4_P"Z#7X[?\'*MYX%^'?_``56_9B\+_MM^%?$%[=9M&\/K*MI)./%7ASPU::;K?B_ M[&UNVKSPQB,W+HSNP=PH+$L2S9;C.!WU`'\QW_!*3_@D9^SQ_P`%=?\`@H)^ MUOX<_:4^)/Q#T:W\!^/KB?1CX(URVM6D:ZU;4ED$OVFUN`P`@3;M"XR`RLS00S63.TEON*I*%VG[Q M?]P_'?Q!\!_"WPK>>.OB9XUTGP[HFGQ^9?ZQKFHQ6EK;)_>DEE940>Y(K\M/ M^"''_!&_]J'X5_M6^+O^"M7_``4C^(VC:_\`%SX@6<[Z/IF@W\=W!I\=YL,M MR\T/[DL852&*.$M%'"Q`8Y4)\G_\%1_C[\)/^"F'_!?1?V#/VTOVI-+^&_[- MOP7AWZU;:MXJBTFTUG48K:.6=6FED53:_-+_@HW^QQ_P`&R/Q*_8U\46'[ M*?[17[/O@3XD^%O#MQJ/@#6_!WQ1LDO+C4+:)I8;:8?:F-R)F01EGW2*7#*< MC!W?V)?V^OB7^WS_`,&M/Q]UKXU^(KC6/%_P]^'GBGPEJ^M7LA>XU..'2EGM MKF5CR\A@N$C9R2SM"S,26)H`]S_X-)[JXNO^",OA:>[N'D<^--?!>1BQ_P"/ ML]S7VQ^T#^WG^Q1^REJ4&B?M*?M7?#_P/?W*![?3?$WBNUM+F5#T=87<2%?] MH+CWK\HO^".'[7FH_L(?\&K/BS]JK08()-7\*WOB-M`2Y7=&=2GOUMK0NN1N M03S1LR]U4BO%_P#@B5\#_P#@BO\`%'X)7G[;O_!7C]KGX3>._C7\1];OKS4- M%^*WQ(LQ+H\"SO$OG6DUPI:>4H9=TJG;&\2HJ@$L`?O;\$_VB/@)^TIX3_X3 MS]GKXT>%O'&B^9Y;:IX4UZWOX$?&=C/"[!6_V3@^U=!XL\7^$_`?AV[\7>.? M$^GZ-I.GPF6_U35;U+>WMHQU>220A44>I(%?SG?M)?&7]AG_`((\_P#!6CX. M?M1?\$A/VGO".L?#/XB7ZZ;\7_AQX'\:G3+*LB(821;JL41D9?*:69P3D`@'T19?\`!8'_`()5ZCXE7PC9 M?\%%/@S)?M((TC7XB:?L=ST42>;L)YQ@-UXZU]#:5JVEZ[IEOK6B:E;WEG=P MK-:W=K,LD4T;#*NC*2&4@@@C@@U^._[??[*G_!JQX0_95\5?#9O%7P,\*>(; M/PW=+XZU7Q1X$\0^(+#X7Q7,OF&WF?1K>ZM;5`YP$%Y*[`$X_>D<` M4`?IS\=/^"CO[`G[,GBH^!?V@OVR?AKX/UP`,^BZ]XPM(+R-2,AGA9]Z`]BP M`KO?@]\>?@A^T-X3'CSX"?&'PQXUT0R>6-7\*:];ZA;;\`[#)`[*&P0<9SS7 M\WW_``0F^(/_``0D'A7QGX:_X+`:'ILGQWU3QQ>G4]9^,6GW=Q:R0ML^43,& MBMIQ,)S*UQLD+'[Y&`/TQ_X)G?\`!'WX6?LO?\%$/$/[=_\`P3E_;!\,R_`# MQAHKV=Y\,?#5ZVKVL\CQ*PV7:W+1H(KE1+&2'=4>2($*Y-`'Z0_$3XE_#GX1 M>$KOQ_\`%?Q]HOAG0K!-]]K7B#5(K.TMU]7EE947\37E7P;_`."E_P#P3S_: M&\:I\-_@?^VS\+_%/B"5]EMHNB^-;.>ZN#G'[J)9-TO_```'MZU^*7[?GQU^ M!_\`P5._X.`-7_9$_;U_:FT?X>?LV_`A)UETK7/%T6CV>MZC:B&.XB,LLBJ; MF6YG:/*GS%MK9PFQMSUZ;_P5#_9&_P"#:[QS^Q?XIUO]C/\`:.^`G@/XJ^"/ M#UQK'@#4O`?Q/LDO+^^M(FFCLG1;HFX:E%?!?\` MP;=_MY_$/_@H'_P2_P##WQ"^,.MRZKXO\&Z[=^$?$>LW#;I=1EM8X)8;B0]6 ME:VN;?>QY9PS'EJ^]*`"BBB@#@OVE_V=_`/[4_P:UCX+?$>U9]/U6$>7/%Q) M:SJ=T&9KG16F(TKQ190,UG>) MV.[_`)9O@\HV"#TR.:_H8JKK.AZ-XBTV71]?TFVO;2=2LUK=P+)'(#V96!!' MUKV,JSFOEDFDN:#W7ZH^`XW\/\MXRIQJ2E[.O%64TKZ=I+2Z[:W7X'\Q.1ZU MV'P4^`GQ?_:(\8P^`_@YX$O]S4O^">O M[$6KZL-;O_V7_!S7(8MO31T1A^7X#P*Q/UI/&8N/LU_)%\S7ST7XGA?_ M``3>_8#\/?L,?"232KR[@U+Q?KI2;Q-J\(.PE<[((L\^6FX\\;B2QZ@#Z/`P M,4`8XHKXZO7JXFLZM1W;/Z`RS+<%D^`IX/"0Y:<%9+^MV]V^K"BBBLCO"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`K\-?VTO^5R[X`?]B7:?^F_6:_,/@^UW\7?"UDEIH7BL>(=0C%M"L2+B$]0MRPX`"K_`&7U\U_M;_\`!(3_`()W?MS_`!CT M+]H#]J#]G6W\1>,?#=M#;Z3KD&OZCI\J113&:)9!9W$2S[')*^8&P"0.#B@# M\U_^#QS]GKQ$]C\`?VX1\/F\3>$OAYXDN-,\$V]Q/:SP+-C[L4IMYH M68\;I8USEE!^D_@3^Q%_P;.?M$_LZ6?[4_P\^`/P1/@Z;3%O;_4-1O4MCI7R M;GBO%DF!MI4Y#(^"".X()_1/QUX#\%?$_P`':G\/?B-X3T[7="UFSDM-6T?5 MK-+BVO('&'CDC<%74@\@BOS^\7?\&J?_``19\6>,YO%Z?L[:UI45Q/YL^BZ1 MXYU*&Q9MQ)`0S%HU.<;490HX4+0!X[_P0N^.?_!.+]I7]O[XH6__``3]_P"" M6OA_P1X;^&UEASSVIV!-7:Q-CO'/)BG@T MJY;UWGO7[M?LR?LH_LZ_L:?"NU^"G[,'PCT?P;X9M)&D33=(@(\V5@`TLLC$ MR3RD``R2,SG`R>!7#_MS?\$R/V(O^"DFD^'M$_;.^":>,+?PK<7$^@8UZ_T] M[5YU19/_``E&B+:? M%V0QQXD)NIV+NW?Y-*NAGT\H?W:3_@W=\9_$#_@J[_P5PU__`(*/?%[3)7A^ M#_P6T+PSIAGPPCU>6PCLY)5/82>5JLV!R/M*_C^Y_B#X&_"KQ3\#;W]FW7/! M]O-X(U'PK)X;N]`$CI$^EO;&U:VW*P=5\DE,A@P'(.>:\^_8?_X)T_L<_P#! M.+P1K/P[_8W^#R>$-)\0:J-1UB$ZU>W\ES<")8E8RWLTL@4(H`0,%!+$#+,2 M`?)W_!2+_@J]^S;\'?\`@H+X,_X)A_\`!0+]D+PY=_"?XBZ5#>Q?$_QQJ,-S MI"R2+-&@>SFM&2/9=1K$TIF'E"593M6OD3_@NG_P1I_X(B?`S]BGQ9^UQ\!_ M%&F?#'QM86"WG@JT\+>-3/9^(;TNOEVT=G+)+D,"<-;>6(Q\YRJD5^O'[9G[ M`G[(G_!03X=P_"_]KKX):7XPTNTF:;3GN7D@NK"4C#/;W,#)-`2``VQP&``8 M$#%?*7PN_P"#6K_@C#\+_&UOXX7]FW4?$,MG,);33O%'BZ^O+*-@1GN[[2X MKR:.RFE9_F8F!4`-9K]0/^"HG_!. M?X0_\%/?V1O$/[-7Q0M(8+Z>%KOPAXB,`:;0]513Y%RAZ[?%_\`9D^$#>&_$/Q,OA=^-K]O$6H7G]HS"::8-Y=U M<2)#^\N)FQ$J#Y\8P`![K0!^''_!LQ_P43^+_P"SM\*M5TNXCDLY/ M,MI6%C=0I))&<`2.K-M55)*JH'H/[77[#_[*?[>/PT_X5'^UI\%-'\9Z(DIE MM8]05XY[.4C:9+>XA9)K=\<%HW4D<'B@#X)_;M_94_X-O/V$_P!E36_VGO&O M[)WP:U6.'2))_"6B:=?K)/XDO"A-O;6WERL6#N5!D4,L:DNW"FN5^"7BOX,_ M%7_@VH_:(^.OP)_8$T[]GC0/&7P]\5W=GX6TS66OH]62+3?(&IAVAB*B1HWC M52OW8`P)#`U[/\,_^#6?_@C#\-/&]OXX7]F_4M?>TG$UKI?B;Q??7=BC!L@- M`9`LRCILEWJ1U!K[>^)?P"^$/Q=^!>L_LT^./!-M-X'U[PY+H.I>'K&1[.%M M-DA,+6T9MV1H5\L[1Y94J,;2,"@#\4/^";G[,7C3]L#_`(-#?'OP*^&VF37W MB*^O->OM$T^W&9+RYLM3CO4MT'=Y/LYC4=V<55_X-T?@5_P0\_;7_8VTOX4? MM&?LX?#:X^.7@JYN[/Q=9>*OW&H:I#]HD>"\C5I%\U1$Z1/M&4>$[@-REOV; M_9#_`&-_V<_V$/@K:_L\?LL?#YO#'A"ROKB[MM);5[N^*33OOE;S;N664Y;G M!;`[`5\[_M>_\&]?_!*/]M?XD7?QB^+/[-RZ=XJU&8W=C0!\&_M0>(?^"&'P8_X*-_#3_@GQ^R%_P`$F?AO\;/& M/BC5(;;Q!?>&O$#6T/AJ=YDV9D6.=)FBB6:>93J0L[2^DN?M)>ZDD?]V&>:);)9 M7!6$!F&,OG]9OV$?^"/_`/P3W_X)O7-QK?[*7[/UEI&NWML;>]\4:G>SZAJ< MT1QE!/<.[1(V`2D6Q"0,KQ6U^W;_`,$P/V(?^"DWAG3O#G[7OP0L_$DFC%SH MNL07^(AX5NU\%6&O:])KNHZSJ3P.ML+>&ZGFW$RE29%0)&,L2H%>2? M\&D?Q/\`$_P;_P""0_[0_P`4?`OP[E\9:YX5\>ZCJ]CX/M+[[/<:L\&AV]3R&%>U_L7?\$V_P!C7_@GK_PE4?[(7PEE\)0^ M-+^*]\16P\1ZC>PW%Q'YFQUCN[B5(2!(X_=!`1@'(5<`'P;^Q[XX_P""*7_! MQK\']3^*_P"TM^R9\.?#OQ1M=5N;7Q)X=D\0"WU^"%#^XN?MUNMI<74;1%?G M*E5=73^&OBKX`?!'X=?\$Y/^#F7X9_LR?\$EOCUK'BWP1XBLH/\`A9NBQZ\M M_;6$+_:VOK&>6%=DPM[>&"Y1G!>.1U0MN4U^I_[3W_!MW_P2+_:N^)5]\7O' M'[-LFB>(=5N6N-7OO!NOW6EQWLK$EG>WB?R`[,2S.L:LQY8FO7_V$_\`@D]^ MP/\`\$W(;Z;]D?X`V/A_5-4MA;ZIXBN[R>^U*ZB#!O+:XN7=TC+*K&-"J$J# MMR!0!^*/Q;^!?['/[(__``ZA-!<1WC2`@(B3QW=F[$A8_-#OM4;A]Q?\%#OV9?^#<7_`()\?LIZU^TC MXO\`V/\`X.:W=IICOX,\,:??AKCQ)?,A\BWA\N1V\MFQOF"LL:;G.<`'[Z_; M%_8+_9&_;]^'D?PO_:Y^!^D>,M*MI&DT]KSS(;JPD889[>YA9)H&(`!,;KN` M`.17RG\)?^#7+_@C-\)?'5MX]A_9MO\`Q%/93B6ST_Q7XKO;VRB<'(W6YD"3 M#MME#J>X-`'??\$'-?\`A%\0/^"?.D?&3X'_`+"=A^SWX=\;Z[=ZQ9>"].U< MWJ7R[(;==3WM#$1YRVZA04Y2)&!(8&OLRH-,TS3=$TVWT;1M.@M+.T@2&UM+ M6%8XX8U`5415`"J```!P`,5/0`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% F%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?_]D_ ` end